RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF HUMAN SURFACTANT GIVEN AT BIRTH VERSUS RESCUE ADMINISTRATION IN VERY-LOW-BIRTH-WEIGHT INFANTS WITH LUNG IMMATURITY

被引:118
作者
MERRITT, TA
HALLMAN, M
BERRY, C
POHJAVUORI, M
EDWARDS, DK
JAASKELAINEN, J
GRAFE, MR
VAUCHER, Y
WOZNIAK, P
HELDT, G
RAPOLA, J
机构
[1] UNIV CALIF SAN DIEGO, DEPT PEDIAT, SAN DIEGO, CA 92103 USA
[2] UNIV CALIF SAN DIEGO, DEPT RADIOL, SAN DIEGO, CA 92103 USA
[3] UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92103 USA
[4] UNIV CALIF SAN DIEGO, DEPT COMMUNITY MED, SAN DIEGO, CA 92103 USA
[5] UNIV CALIF SAN DIEGO, GEN CLIN RES CTR, SAN DIEGO, CA 92103 USA
[6] UNIV HELSINKI, CHILDRENS HOSP, DEPT PEDIAT, SF-00100 HELSINKI 10, FINLAND
[7] CHILDRENS HOSP & HLTH CTR, DIV NEONATOL, SAN DIEGO, CA USA
关键词
D O I
10.1016/S0022-3476(05)83387-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
A randomized, placebo-controlled trial of human surfactant given intratracheally at birth (prophylactic) versus rescue administration after the onset of severe respiratory distress syndrome (RDS) was conducted among preterm infants born at 24 to 29 weeks of gestation. Singleton fetuses were randomly assigned to receive (1) placebo (air), (2) prophylactic surfactant treatment, or (3) rescue surfactant treatment; infants of multiple births received either (1) prophylactic or (2) rescue treatment. Of 282 potentially eligible fetuses, 246 infants received treatments at birth and 200 infants had RDS. Outcomes are presented both as an intention-to-treat analysis (including infants who met exclusion criteria at or after birth) and as a full treatment protocol analysis for those infants with RDS and likely to benefit from surfactant. Preterm infants (mean 1.0 kg birth weight, 27 to 28 weeks of gestational age) randomly assigned to receive prophylactic treatment received surfactant soon after birth; those assigned to receive rescue surfactant had instillation at a mean age of 220 minutes if the lecithin-sphinogomyelin ratio was less-than-or-equal-to 2.0 and no phosphatidylglycerol was detected in either amniotic fluid or initial airway aspirate, oxygen requirements were a fraction of inspired oxygen of > 0.5, and mean airway pressure was greater-than-or-equal-to 7 cm H2O from 2 to 12 hours after birth. Up to four treatment doses (or air) were permitted within 48 hours; approximately 60% of surfactant-treated infants required two or more doses. Surfactant-treated infants had significantly less pulmonary interstitial emphysema than placebo-treated infants (p = 0.02), but there were no other significant differences in mortality rates or morbidity. Indexes of oxygenation and ventilation were improved in surfactant recipients during the first 24 hours. An intention-to-treat analysis found no significant differences between infants
引用
收藏
页码:581 / 594
页数:14
相关论文
共 43 条
[1]  
AMENTA JS, 1987, CLIN CHEM, V33, P647
[2]  
APILLMAN T, 1988, CLIN CHEM, V34, P1976
[3]  
BEJAR R, 1986, AM J NEURORADIOL, V7, P1073
[4]  
Bishop Y., 1975, DISCRETE MULTIVARIAT
[5]  
DUNN MS, 1990, PEDIATRICS, V86, P564
[6]   RESPIRATORY-DISTRESS SYNDROME TREATED WITH HUMAN SURFACTANT - RADIOGRAPHIC FINDINGS [J].
EDWARDS, DK ;
HILTON, SV ;
MERRITT, TA ;
HALLMAN, M ;
MANNINO, F ;
BOYNTON, BR .
RADIOLOGY, 1985, 157 (02) :329-334
[7]   FORCING A SEQUENTIAL EXPERIMENT TO BE BALANCED [J].
EFRON, B .
BIOMETRIKA, 1971, 58 (03) :403-&
[8]  
ENHORNING G, 1985, PEDIATRICS, V76, P145
[9]  
FUJIWARA T, 1980, LANCET, V1, P55
[10]  
GARNER A, 1984, PEDIATRICS, V74, P127